INVA

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
George WhitesidesDemocrat $375k OtherMar 25, 2025 $250k-$500k -- --
George WhitesidesDemocrat $375k OtherMar 25, 2025 $250k-$500k -- --
George WhitesidesDemocrat $75k OtherMar 24, 2025 $50k-$100k -- --

Insider Trades

Name	Value	Action	Price	Current Price
Denner Alexander J10 Percent Owner $21M1.2M shares SellMar 6, 2025 $17.52 --
Denner Alexander J10 Percent Owner $4.8M270.4k shares SellMar 5, 2025 $17.63 --
Denner Alexander J10 Percent Owner $2.7M151.2k shares SellMar 4, 2025 $17.63 --

News

seekingalpha.comInnoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

gurufocus.comInnoviva to Participate in Upcoming Investor Conferencesgurufocus.comJun 1

businesswire.comInnoviva to Participate in Upcoming Investor Conferencesbusinesswire.comJun 1

fool.comInnoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million Morefool.comMay 29

zacks.comInnoviva (INVA) Tops Q1 Earnings Estimateszacks.comMay 6

Trade INVA

About Innoviva, Inc.

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

CEO: Pavel Raifeld
IPO Date: Oct 5, 2004

Market Data

Open: $22.95
High: $23.00
Low: $22.22
Volume: 1.4M
Avg Volume: 785.4K
52W High: $25.15
52W Low: $16.52

Valuation

Market Cap: $1.7B
Enterprise Value: $1.4B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $186M
Revenue: $425M
Net Income: $271M
Cash: $551M
Debt: $269M

Events

EarningsAug 5

EPS est. 0.436